STAT

JUNE 2, 2024

CHICAGO — Comfort can be delivered to patients with advanced cancer virtually just as well as in person, according to a new study  presented on Sunday at the American Society of Clinical Oncology annual meeting in Chicago. That’s welcome news to palliative care experts who have, in many cases, preferred the convenience and efficacy of telehealth sessions for both themselves and their patients since the Covid-19 pandemic forced virtual visits.

Hospitals 136

Hospitals 136

Drug Topics

JUNE 2, 2024

In case you missed it, this week we had news about AI's role in promoting skin cancer awareness, the legalization of edible cannabis, expanding the role of the pharmacist, and more.

98

98

Fierce Pharma

JUNE 2, 2024

A 50% improvement on the time patients could live without disease progression would typically be considered remarkable for a new drug. AstraZeneca’s Tagrisso just delivered an 84% improvement. | A 50% improvement on the time patients could live without disease progression would typically be considered remarkable for a new drug. AstraZeneca’s Tagrisso just delivered an 84% and earned a standing ovation at ASCO 2024.

121

121

Pharmacy Times

JUNE 2, 2024

Matthew A. Gubens, MD, MS, FASCO, highlights the importance of identifying genetic targets in metastatic non–small cell lung cancer (NSCLC), emphasizing the latest updates and strategies.

FDA 116

FDA 116

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

STAT

JUNE 2, 2024

Intellia Therapeutics said Sunday that the first 10 patients to receive a CRISPR-based treatment for hereditary angioedema, a genetic disease, saw their swelling attacks — the condition’s hallmark symptom — virtually eliminated for an average of 20 months and counting. The attacks were reduced by an average of 98%. One patient has remained attack-free for 26 months.

113

113

pharmaphorum

JUNE 2, 2024

An AI tool has shown impressive results in raising colorectal cancer screening rates in underserved populations, according to data presented at ASCO

121

121

STAT

JUNE 2, 2024

The body mass index has long been slammed as a blunt instrument for evaluating health, even more so with new obesity drugs changing the conversation about weight and well-being. Now a study reasserts BMI’s value as a screening tool in children to detect high levels of body fat, a measure tied to greater risk of cardiovascular disease, early atherosclerosis, and a high BMI in adulthood.

100

100

Pharmacy Times

JUNE 2, 2024

Understanding patients’ specific experiences and challenges is crucial to helping them improve medication adherence.

119

119

STAT

JUNE 2, 2024

You’re reading the web edition of ASCO in 30 Seconds, STAT’s guide to the American Society of Clinical Oncology annual meeting. Sign up here. CHICAGO — It’s Sunday and the gorgeous June weather in Chicago has returned. But fear not, we’re inside writing about cancer drugs and research for you. Who remembers the car chase scene from the Blues Brothers movie?

91

91

Pharmacy Times

JUNE 2, 2024

Results from the trial provide evidence bolstering ASCO’s clinical practice guideline supporting the integration of early palliative care into standard oncology practice.

94

94

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

pharmaphorum

JUNE 2, 2024

ASCO: Gilead sifts lung cancer data for efficacy crumbs Phil.

100

100

Pharmacy Times

JUNE 2, 2024

Data presented at ASCO 2024 show fam-trastuzumab deruxtecan-nxki (T-DXd) delayed cancer growth in patients with hormone receptor-positive (HR+), HER2-low or -ultralow disease that progressed following endocrine therapy (ET).

65

65

BioPharm

JUNE 2, 2024

Asking why things are done a certain way will help make an accurate assessment of an organization’s EM program, says Susan Schniepp, distinguished fellow at Regulatory Compliance Associates, and Zachary S. Anderson, global market segment lead—Sterility Assurance, Nelson Laboratories.

52

52

Med Ed 101

JUNE 2, 2024

Osteoarthritis is one of the most common pain syndromes in the aging adult. Medications are often used to reduce pain and increase quality of life. In this article, I will review osteoarthritis pharmacotherapy and discuss some of my most important practice pearls. Location, Location, Location One of the things that I look at first is […] The post Osteoarthritis Pharmacotherapy – Practice Pearls appeared first on Med Ed 101.

52

52

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management Software

Pharmacy Times

JUNE 2, 2024

The phase 3 LAURA trial data presented at ASCO 2024 showed osimertinib (Tagrisso; AstraZeneca) reduced risk of disease progression or death in patients with stage 3 EGFR-mutated (EGFRm) non–small cell lung cancer (NSCLC) by 84%.

65

65

Pharmaceutical Technology

JUNE 2, 2024

If Enhertu gets approved in the first-line setting metastatic breast cancer setting, 4,200 patients a year could be eligible to receive it.

52

52

The FDA Law Blog

JUNE 2, 2024

By Adrienne R. Lenz, Principal Medical Device Regulation Expert — FDA’s Office of Women’s Health (OWH) recently celebrated its 30th anniversary. This office was formed in 1994 to promote the inclusion of women in clinical trials and to provide leadership on topics related to the health of women. Given that FDA was founded in 1906 and the Federal Food, Drug and Cosmetic Act went into effect in 1938, the OWH’s thirty years of existence, while an important milestone, constitutes a very small amou

FDA 64

FDA 64